Is Multidrug Resistance (P-Glycoprotein) an Intrinsic Characteristic of Plasma Cells in Patients with Monoclonal Gammopathy of Undetermined Significance, Plasmacytoma, Multiple Myeloma and Amyloidosis?

References

• Tiirikainen I. M., Syrjala T. M., Jansson E. S., Krusius T. Flow cytometric analysis of P-glycoprotein in normal and leukemic cells. Annual of Hematology 1992; 65: 124–130
   PubMed Web of Science ®Google Scholar
• Efferth T., Mattern J., Volm M. Immunohistochemical detection of P-glycoprotein, glutathione S-transferase and topoisomerase II in human tumors. Oncology 1992; 49: 368–375
   PubMed Web of Science ®Google Scholar
• Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 1992; 69: 2603–2609
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesman M. Multi-drug resistance in human cancer. New England Journal of Medicine 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H., Koba B. P-glycoprotein expression in plasma cell myeloma associated with resistance to VAD. Bood 1989; 74: 913–7
   PubMed Web of Science ®Google Scholar
• Trumper L. H., Ho A. D., Wulf G., Hunstein W. Additional of verapamil to overcome drug resistance in multiple myeloma: Preliminary clinical observation in 10 patients. Journal of Clinical Oncology 1989; 7: 1578–9
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44–50
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Schoester M., De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistance tumor cells. Journal of Clinical Oncology 1994; 12: 1584–91
   PubMed Web of Science ®Google Scholar
• Grogan T. M., Spier C. M., Salmon S. E., Matzner M., Rybski J., Weinstein R. S., Scheper R. J., Dalton W. S. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Belch A. R. Circulating monoclonal B-cells expressing P-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 1994; 83: 724–736
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H., Oba B. K. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913–917
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B. G., Lokhorst H. M., Frutiger Y., Vela E. E. Analysis of multidrug resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. British Journal of Haematology 1993; 83: 63–67
   PubMed Web of Science ®Google Scholar
• Mark D. C., Su G. M., Davey R. A., Davey M. W. Extended multidrug resistance in haematopoietic cells. British Journal of Haematology 1996; 95: 587–95
   PubMed Web of Science ®Google Scholar
• Lehne G., De Angelis P., Clausen O. P., Egeland T., Tsuruo T., Rugstad H. E. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry 1995; 20: 228–37
   PubMedGoogle Scholar
• Frey T., Yue S., Haugland R. P. Dyes providing increased sensitivity in flow cytometric dye-efflux assays for multidrug resistance. Cytometry 1995; 20: 218–27
   PubMedGoogle Scholar
• Quillet-Mary A., Mansat V., Duchayne E., Come M. G., Allouche M., Bailly J. D., Bordier C., Laurent G. Daunorubicin induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 1995; 10: 417–25
   Web of Science ®Google Scholar
• Alexanian R., Dimopolous M. The treatment of multiple myeloma. New England Journal of Medicine 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Crowley J. Impact of glucocorticoids and interferon on outcome in multiple myeloma. Proceedings of the American Society of Clinical Oncology 1992; 11: 316a
   Google Scholar
• Kyle R. A., Greipp P. R., Gertz M. A. Treatment of refractory multiple myeloma and considerations for future therapy. Seminars in Oncology 1986; 13: 326–33
   PubMed Web of Science ®Google Scholar
• Buzaid A. C., Durie B. G. M. Management of refractory myeloma: a review. Journal of Clinical Oncology 1988; 6: 889–905
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E. Treatment of plasma cell myeloma. Annual Review of Medicine 1979; 30: 431–33
   PubMed Web of Science ®Google Scholar
• Palmer M., Belch A., Hanson J., Brox L. Reassessment of the relationship between M-protein decrement and survival in multiple myeloma. British Journal of Cancer 1989; 59: 110–12
   PubMed Web of Science ®Google Scholar
• Belch A., Shelley W., Bergsagel D., Wilson D., Dlimo P., Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding myeloma patients. British Journal of Cancer 1988; 57: 94–99
   PubMed Web of Science ®Google Scholar
• Greipp P. R. Advances in the diagnosis and management of myeloma. Seminars in Hematology 1992; 29: 24–45
   PubMed Web of Science ®Google Scholar
• Mechetner E. B., Roninson I. B. Efficient inhibition of P-glycoprotein mediated multidrug resistance with monoclonal antibody. Proceedings of the National Academy of Sciences of the United State of America 1992; 89: 5824–5828
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Arceci R. J., Smit J. J. M., Wagenaar E., Bass F., Dolle M., Tsurno T., Mechetner E. B., Roninson I. B., Borst P. Binding properties of monoclonal antibodies recognizing external epitopes of human MDR-1 P-glycoprotein. Cancer 1993; 55: 478–484
   Web of Science ®Google Scholar
• Cumber M. P., Jacobs A., Hoy T., Fisher J., Whittaker A. J., Tsuruo T. Expression of the mulitdrug resistance gene (MDR1) and epitope masking in chronic lymphatic leukemia. British Journal of Haematology 1990; 76: 226–30
   PubMed Web of Science ®Google Scholar
• Cumber M. P., Jacobs A., Hoy T., Whittaker A. J., Tsuruo T., Padua A. R. Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein. Leukemia 1991; 5: 1050–53
   PubMed Web of Science ®Google Scholar
• Xie X. Y., Robb D., Chow S., Hedley D. W. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 1995; 9: 1882–87
   PubMed Web of Science ®Google Scholar
• Mongkonsritragoon W., Kimlinger T., Ahmann G., Greipp P. R. Unmasking of P-glycoprotein by a commercial lysing solution. Cytometry 1997, submitted
   Google Scholar
• George E., Tsuruo T., Ling V. Topology of P-glycoprotein as determined by epitope mapping of MRK16 monoclonal antibody. Journal of Biology and Chemistry 1993; 268: 1792–8
   PubMed Web of Science ®Google Scholar
• Sugawara I., Kodo H., Ohkochi E., Hamada H., Tsuruo T., Mori S. High level expression of MRK16 and MRK20 murine monoclonal antibody defined proteins (170,000–180,000 p-glycoprotein and 85,000 protein) in leukaemias and malignant lymphomas. British Journal of Cancer 1989; 60: 538–41
   PubMed Web of Science ®Google Scholar
• Dalton W., Greipp P., Greenberg P., Stiff P., Ballester O., Friedenberg W., Salmon S., Kyle R., Charmick S., Pearce T. Phase I study of the chemosensitizer SDZ 833 in reverse multidrug resistance. Blood 1996; 88(Suppl 1)662a
   Google Scholar
• Sonneveld P., Schoester M., De Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. Journal of Clinical Oncology 1994; 12: 1584–1591
   PubMed Web of Science ®Google Scholar
• Bates S. E., Regis J. I., Robey R. W., Zhan Z., Scala S., Meadows B. J. Chemoresistance in the clinic: overview. Bulletin du Cancer 1994; 81: 55s–61s
   PubMed Web of Science ®Google Scholar